Open AccessA Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Author(s) -
Martin H. Voss,
Cinta Hierro,
Rebecca S. Heist,
James M. Cleary,
Funda MericBernstam,
Josep Tabernero,
Filip Janků,
Leena Gandhi,
A. John Iafrate,
Darrell R. Borger,
Nobuya Ishii,
Youyou Hu,
Yulia Kirpicheva,
Valérie NicolasMétral,
Anna Pokorska-Bocci,
Anne Vaslin Chessex,
Claudio Zanna,
Keith T. Flaherty,
José Baselga
Publication year - 2019
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-18-1959
Subject(s) - medicine , tolerability , hyperphosphatemia , pharmacokinetics , response evaluation criteria in solid tumors , hypophosphatemia , cancer , pharmacodynamics , oncology , gastroenterology , toxicity , phases of clinical research , urology , adverse effect , calcium
To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of Debio 1347, a selective FGFR inhibitor.